<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336488</url>
  </required_header>
  <id_info>
    <org_study_id>MMPs in lichen</org_study_id>
    <nct_id>NCT04336488</nct_id>
  </id_info>
  <brief_title>Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus</brief_title>
  <official_title>Effectiveness of Matrix Metalloproteinase Neutralizing Agent in Treatment of Oral Lichen Planus: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaylane kadry Ghonima</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will be conducted to evaluate the effectiveness of matrix
      metalloproteinases inhibitors on erosive oral lichen planus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive
      lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity
      as well as the objective disease severity scores will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double equal arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>participant, investigator as well as outcome assessor are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in disease severity score</measure>
    <time_frame>change in disease severity score from baseline to 3 weeks</time_frame>
    <description>Thongprasom disease severity score (5-0)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Orochem (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matrix Metalloproteinase Inhibitors (Orochem)</intervention_name>
    <description>topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus</description>
    <arm_group_label>Orochem (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenacort A,</intervention_name>
    <description>topical application of both drugs 3 times daily for 3 weeks as an active control</description>
    <arm_group_label>Conventional (Control)</arm_group_label>
    <other_name>miconaz gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with erosive OLP confirmed with a biopsy.

          -  patients should have symptomatic lesions

        Exclusion Criteria:

          -  Patients who were under anticoagulant medications, suffering from any systemic
             diseases or having any physical or mental abnormality, pregnant and lactating women,
             smokers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hossam H. AlSabbagh, As. lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>periodontology department, Faculty of dentistry, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <zip>21500</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Jaylane kadry Ghonima</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>matrix metalloproteinase inhibitors, orochem, OLP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Matrix Metalloproteinase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>participants data are not to be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

